Emerging techniques for risk stratification in multiple myeloma. Each of these tools has potential for researching disease biology and for implementation in the clinic for real-time assessment of disease control and/or risk. cfDNA, cell-free DNA; CPCs, circulating plasma cells; CyTOF, mass cytometry time of flight; MGUS, monoclonal gammopathy of undetermined significance; NGS, next-generation sequencing.